Navigation Links
Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
Date:9/19/2013

SEATTLE, Sept. 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia.

The Phase 1 clinical program in healthy subjects established dosing regimens that were well tolerated and associated with high levels of PDE10 target engagement in the brain, supporting advancement of OMS824 into patient-directed trials. In this Phase 2 clinical trial, OMS824 will be administered at various dose levels for two weeks to patients whose antipsychotic medications have been temporarily discontinued or who continue their usual antipsychotic regimen in order to assess the effects of OMS824 as monotherapy and in combination with antipsychotic medications. A variety of cognitive tests will be assessed, although the relatively small size of this trial will limit the ability to detect treatment effects, if present.  The safety and any efficacy findings in this trial are planned for use in determining appropriate dosing regimens and selecting endpoints for subsequent Phase 2 and Phase 3 clinical trials in schizophrenia. Those trials are expected to evaluate OMS824 in schizophrenic patients who are psychiatrically stable with cognitive impairment, in patients with acute exacerbation of symptoms, and/or in patients with inadequate response to antipsychotic medications.

"We are excited to begin assessing OMS824 in patients suffering with schizophrenia," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "This Phase 2 trial will provide us with important info
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Reports Additional Positive Results from OMS824 Program
2. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
3. Omeros to Present at the Stifel Healthcare Conference 2013
4. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
5. Omeros Corporation Reports Second Quarter 2013 Financial Results
6. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
7. Omeros Submits New Drug Application to U.S. FDA for OMS302
8. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
9. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
10. Omeros Corporation Reports First Quarter 2013 Financial Results
11. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... SEATTLE , BERKELEY, Kalifornien, und KOPENHAGEN, ... CMC Biologics, Inc. , ein Weltmarktführer der ... und anderen therapeutischen Proteinen, gab heute bekannt, ... Expansionsstrategie der Produktionskapazität den Ausbau der nordamerikanischen ... , mit der Ergänzung  einer Einweg-Anlage Bioreactor ...
(Date:6/30/2015)... 2015  Marken, the leading clinical trial logistics organization ... has been granted permission by the government to deliver ... product in Korea.  This precedent-setting shipment has allowed several ... continue receiving their clinical trial drugs during the outbreak ... emergency was caused by recent partial closures of medical ...
(Date:6/30/2015)... PharmaVentures is pleased to announce ... Oy (CMT) on its divestment of certain assets to ... world leading capabilities in cellular imaging and analysis. ... of successful global deals in the life science research ... Walton , CEO, PharmaVentures, commented: "PharmaVentures is delighted to ...
Breaking Medicine Technology:CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3Marken Delivers Direct To Patients During MERS Outbreak 2Marken Delivers Direct To Patients During MERS Outbreak 3PharmaVentures Completes M&A Deal for Technology in the Stem Cell & Regenerative Medicine Sector 2
... WORTH, Texas, Aug. 26 Healthpoint today announced,that ... the effectiveness of a,widely prescribed enzymatic debriding agent ... study was prompted, in part, by clinical reports,of ... healing,properties associated with Collagenase SANTYL(R) Ointment.(1,2), "Given ...
... Inc.,(Nasdaq: XTNT ) today announced that the positive ... in the most recent issue of the,peer-reviewed journal, EuroIntervention. ... Stella, M.D., of University Medical Center Utrecht, Utrecht,The Netherlands ... clinical,sites across Europe., The one-year CUSTOM II trial, ...
Cached Medicine Technology:Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4
(Date:6/30/2015)... Chicago, IL (PRWEB) , ... June 30, 2015 , ... ... to educate women on fertility preservation and deciding the right age to pursue egg ... child until after the age of 35 — a 150 percent increase since the ...
(Date:6/30/2015)... ... June 30, 2015 , ... The American Lung Association in ... media event in San Diego. Speakers and clean air advocates included San Diego County ... Germuska of Kindred Hospital, and Daniel Sullivan, founder and president of Sullivan Solar Power. ...
(Date:6/30/2015)... ... June 30, 2015 , ... ADVOCATE, the premier ... been awarded the exclusive billing agreements with Jackson Radiology Associates in Jackson, TN. ... their proprietary suite of billing process software functionality called Experience Based Technology (EBTTM). ...
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... Broadway ... Nursing”, which features multiple patient and family member testimonials. Medicare rated the care center ... Broadway plans to use the video to give future patients a firsthand look at ...
(Date:6/30/2015)... ... June 30, 2015 , ... Family and professional dementia ... Symposium on November 9, 2015 at the Hyatt Regency Denver Tech Center from ... Kim and Ashley Campbell, the wife and daughter of singer Glen Campbell, who ...
Breaking Medicine News(10 mins):Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 2Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 3Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 4Health News:LIV Fertility Center Educating Women on the Critical Timing of Egg Freezing 5Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 2Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 3Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Family of Singer Glen Campbell to Discuss Living with Dementia at the Alzheimer's Association of Colorado's 26th Annual Education Symposium 2
... who are in the process of developing a blood test ... than a mammogram, need the help of thousands of people ... spin-out company Oncimmune pioneers anti-cancer technology, and has reached the ... response to breast cancer. , The initial ...
... can keep disease from recurring , , MONDAY, April 21 (HealthDay ... recurrence of the disease and live longer, yet cancer survivors ... of the general population, according to new research. , ... Cancer , found that less than one-quarter of cancer survivors ...
... That Celebrates Daily Victories Over ... Parkinson,s, ... A number of people with Parkinson,s disease (PD), an age-related,degenerative disorder of ... penned their own inspirational story compiled in a new,book titled "Proud Hands." ...
... Performed at Significantly Reduced Cost at ... Genesis Medical Center -, - New Study Shows Greater than $1,650 Savings Per ... ... CRDC ) and Genesis Medical Center today reported results from a,six-month economic analysis comparing ...
... Outlook Reaffirmed -, MADISON, N.J., April 21 ... provider of diagnostic,testing, information and services, announced that for ... operations was $141 million,or $0.72 per diluted share, compared ... first quarter of 2007. Included in the results for ...
... Echo Therapeutics,(OTC Bulletin Board: ECTE) today ... and transdermal drug delivery technology right of ... capital affiliate of Cato,Research, a global contract ... exclusive rights of first negotiation to all,dermatology ...
Cached Medicine News:Health News:Thousands of volunteers needed to help bring cure for cancer closer 2Health News:Many Cancer Survivors Are Overweight and Sedentary: Study 2Health News:Many Cancer Survivors Are Overweight and Sedentary: Study 3Health News:'Proud Hands' Book Released to Benefit the American Parkinson Disease Association 2Health News:'Proud Hands' Book Released to Benefit the American Parkinson Disease Association 3Health News:'Proud Hands' Book Released to Benefit the American Parkinson Disease Association 4Health News:'Proud Hands' Book Released to Benefit the American Parkinson Disease Association 5Health News:Cardica's C-Port Anastomosis Systems Facilitate Beating Heart Bypass Surgery in Study 2Health News:Cardica's C-Port Anastomosis Systems Facilitate Beating Heart Bypass Surgery in Study 3Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 2Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 3Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 4Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 5Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 6Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 7Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 8Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 9Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 10Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 11Health News:Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies 2Health News:Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: